Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2350]
News [4894]
Articles [202]
Editorials [8]
Conferences [136]
elearning [14]
Isatuximab in combination to treat relapsed/refractory MM
Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma...
Isatuximab in combination to treat relapsed/refractory MM ( Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation )
17 Jun 2018
Development of a risk stratifying prognostic index for ALL
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Development of a risk stratifying prognostic index for ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
17 Jun 2018
Specification of haematopoetic stem cell fate via modulation of mitochondrial...
Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland
Specification of haematopoetic stem cell fate via modulation of mitochondrial activity ( Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland )
17 Jun 2018
Onset and treatment of infantile leukaemia
Dr Anindita Roy - University of Oxford, Oxford, UK
Onset and treatment of infantile leukaemia ( Dr Anindita Roy - University of Oxford, Oxford, UK )
17 Jun 2018
Novel CD22 CAR-T therapy for paediatric leukaemia
Dr Jing Pan - Beijing Boren Hospital, Beijing, China
Novel CD22 CAR-T therapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )
16 Jun 2018
A new anti-CD22 CAR T immunotherapy for paediatric leukaemia
Dr Jing Pan - Beijing Boren Hospital, Beijing, China
A new anti-CD22 CAR T immunotherapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )
16 Jun 2018
EHA Topics in focus : Immunotherapy
Prof John Gribben - Barts Cancer Institute, London, United Kingdom
EHA Topics in focus : Immunotherapy ( Prof John Gribben - Barts Cancer Institute, London, United Kingdom )
16 Jun 2018
Novel ADC for relapsed/refractory lymphoma
Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada
Novel ADC for relapsed/refractory lymphoma ( Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada )
16 Jun 2018
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia
Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School...
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece )
16 Jun 2018
Ribosomal lesions promote oncogenic mutagenesis
Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium
Ribosomal lesions promote oncogenic mutagenesis ( Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium )
15 Jun 2018
Phase II results of olaparib and abiraterone for mCRPC
Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK
Phase II results of olaparib and abiraterone for mCRPC ( Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK )
4 Jun 2018
Design and interim safety analysis of GeparX trial
Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany
Design and interim safety analysis of GeparX trial ( Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany )
4 Jun 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation